Susannah Gray brings more than 30 years of biopharmaceutical experience, specifically in corporate finance and capital markets roles, most recently serving as Executive Vice President, Finance & Strategy of Royalty Pharma Management, LLC. ( NYSE:ZYME), Sophia Genetics, LetsGetChecked, CM Life Sciences II ( NASDAQ:CMIIU) and MassBio. He also currently serves as a director of Zymeworks, Inc. Cox held executive and senior roles, including President UCB BioPharmaceuticals, Senior Vice President Sanofi-Aventis and diverse foundational roles at Schering-Plough. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth to over $12 billion while accountable to help steer the Roche Genentech R&D portfolio. Troy Cox led Foundation Medicine ( NASDAQ:FMI), as President and Chief Executive Officer, through the acquisition by Roche for $5.3 billion in 2018. Cox bring invaluable insight to our company as we continue the buildout of our alternative splicing platform and navigate the final stages of clinical development for our lead osteoarthritis drug candidate, lorecivivint, and continue to develop our promising oncology and neurology pipelines." "We are honored to have this caliber of experience and leadership join our new board at Biosplice," said Osman Kibar, PhD, Founder and Executive Chairman of Biosplice. New directors comprise Troy Cox, former CEO of Foundation Medicine, Susannah Gray, former EVP and CFO of Royalty Pharma Management, and Karen McGinnis, former VP and CAO of Illumina. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board.
0 kommentar(er)
